Orchestra BioMed Holdings, Inc.
orchestrabiomed.comOrchestra BioMed Holdings Inc (NASDAQ: OBIO) is a medical device development company that advances cardiovascular product candidates through a partnership-enabled model, retaining strategic collaborators to fund and commercialize its technology. Revenue is generated through licensing fees, milestone payments, and research and development services billed to partners under collaboration agreements, rather than from commercial product sales. The company's two lead programs are Virtue SAB, a sirolimus-coated balloon catheter targeting coronary artery disease, and AVIM Therapy, an autonomic modulation device for hypertension being developed in collaboration with Medtronic. Orchestra was incorporated in Delaware in January 2017 and is headquartered in New Hope, Pennsylvania, with additional R&D operations in Fort Lauderdale, Florida. Research and development expenses totaled $58.2 million for the year ended December 31, 2025, up from $42.8 million for the year ended December 31, 2024. Neither lead product has received commercial approval as of the filing date of March 12, 2026.
Products & Services
Virtue SAB: a sirolimus-coated balloon catheter for coronary artery disease treatment. AVIM Therapy: an autonomic modulation device for hypertension, co-developed with Medtronic. Both products are pre-commercial as of the 10-K filed March 12, 2026. The company also holds a pipeline of earlier-stage product candidates intended for future partnership arrangements.
Revenue Model
Collaboration and licensing revenue from strategic partners, including upfront license fees, milestone payments, and reimbursed R&D services. In August 2025, Orchestra also entered a revenue participation right agreement with Ligand Pharmaceuticals, receiving $35.0 million in exchange for tiered future revenue interest on net product sales of Virtue SAB and AVIM Therapy.
Customers & Markets
Strategic partners and licensees serve as primary revenue counterparties, including Medtronic for AVIM Therapy and Terumo under a separate collaboration agreement. End markets are cardiovascular medicine, specifically hypertension and coronary artery disease treatment, with physicians, hospitals, and third-party payors as the ultimate customer base upon eventual commercialization.
Geographic Exposure
R&D operations based in New Hope, Pennsylvania and Fort Lauderdale, Florida. Regulatory focus is on U.S. FDA approval pathways, with potential international filings subject to foreign regulatory authority requirements.
Financial Snapshot
Loading...
